Guide to European Society of Cardiology (ESC). Management of patients with ST-segment elevation acute myocardial infraction: Workgroup of the European Society of Cardiology on the management of ST-segment elevation, acute heart attack;Guías de Práctica Clínica de la Sociedad Europea de Cardiología (ESC). Manejo del infarto agudo de miocardio en pacientes con elevación persistente del segmento ST-Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) sobre el manejo del infarto agudo de miocardio con elevación del segmento ST (IAMCEST)

Revista Espanola de Cardiologia

Volumn 62, Issue 3, 2009, Pages

  Van De Werf, Frans ^a,b   Bax, Jeroen ^a   Betriu, Amadeo ^a   Blomstrom Lundqvist, Carina ^a   Crea, Filippo ^a   Falk, Volkmar ^a   Filippatos, Gerasimos ^a   Fox, Keith ^a   Huber, Kurt ^a   Kastrati, Adnan ^a   Rosengren, Annika ^a   Steg, P Gabriel ^a   Tubaro, Marco ^a   Verheugt, Freek ^a   Weidinger, Franz ^a   Weis, Michael ^a  

^a University Hospitals Leuven ^*

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE; ALTEPLASE; ATENOLOL; ATROPINE; CLOPIDOGREL; DOBUTAMINE; DOPAMINE; ENOXAPARIN; EPTIFIBATIDE; FONDAPARINUX; FUROSEMIDE; GLYCERYL TRINITRATE; HEPARIN; HIRULOG; INOTROPIC AGENT; ISOPRENALINE; LIDOCAINE; METOCLOPRAMIDE; MORPHINE; NITRATE; PLACEBO; PROPRANOLOL DERIVATIVE; RETEPLASE; SOTALOL; TENECTEPLASE; TIROFIBAN; UNINDEXED DRUG; VERAPAMIL;

ANGIOGRAPHY; BLEEDING; BLOOD VESSEL OCCLUSION; BRADYCARDIA; BRONCHOSPASM; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOGENIC SHOCK; CLINICAL FEATURE; CLINICAL PRACTICE; CORONARY ARTERY BLOOD FLOW; DEEP VEIN THROMBOSIS; DEFIBRILLATOR; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; EARLY INTERVENTION; HEALTH CARE DELIVERY; HEART ARRHYTHMIA; HEART BLOCK; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE SEPTUM RUPTURE; HUMAN; HYPOTENSION; INFLUENZA VACCINATION; KIDNEY DYSFUNCTION; LIFESTYLE MODIFICATION; LUNG EMBOLISM; MITRAL VALVE REGURGITATION; NAUSEA AND VOMITING; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PERICARDITIS; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PSYCHOLOGICAL ASPECT; RADIODIAGNOSIS; REPERFUSION; RESPIRATION DEPRESSION; REVIEW; SECONDARY PREVENTION; SOCIOECONOMICS; ST SEGMENT ELEVATION; THORAX PAIN; TREATMENT DURATION;

EID: 64149095804     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/S0300-8932(09)70373-2     Document Type: Editorial

References (258)

1. K. Thygesen, J.S. Alpert, and H.D. White Universal definition of myocardial infarction Eur Heart J 28 2007 2525 2538
2. J.P. Bassand, C.W. Hamm, D. Ardissino, E. Boersma, A. Budaj, and F. Fernandez-Aviles Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes Eur Heart J 28 2007 1598 1660
3. V. Fuster, P.R. Moreno, Z.A. Fayad, R. Corti, and J.J. Badimon Atherothrombosis and high-risk plaque: part I: evolving concepts J Am Coll Cardiol 46 2005 937 954
4. G.A. Rodríguez-Granillo, H.M. García-García, M. Valgimigli, S. Vaina, C. Van Mieghem, and R.J. Van Geuns Global characterization of coronary plaque rupture phenotype using three-vessel intravascular ultrasound radiofrequency data analysis Eur Heart J 27 2006 1921 1927
5. R. Detrano, A.D. Guerci, J.J. Carr, D.E. Bild, G. Burke, and A.R. Folsom Coronary calcium as a predictor of coronary events in four racial or ethnic groups N Engl J Med 358 2008 1336 1345
6. S.Z. Rittersma, A.C. Van der Wal, K.T. Koch, J.J. Piek, J.P. Henriques, and K.J. Mulder Plaque instability frequently occurs days or weeks before occlusive coronary thrombosis: a pathological thrombectomy study in primary percutaneous coronary intervention Circulation 111 2005 1160 1165
7. G.K. Hansson Inflammation, atherosclerosis, and coronary artery disease N Engl J Med 352 2005 1685 1695
8. P. Libby, and P. Theroux Pathophysiology of coronary artery disease Circulation 111 2005 3481 3488
9. K.W. Lee, G.Y. Lip, M. Tayebjee, W. Foster, and A.D. Blann Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes Blood 105 2005 526 532
10. P.H. Stone Triggering myocardial infarction N Engl J Med 351 2004 1716 1718
11. M.J. Davies The pathophysiology of acute coronary syndromes Heart 83 2000 361 366
12. E.C. Keeley, J.A. Boura, and C.L. Grines Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials Lancet 367 2006 579 588
13. H. Tunstall-Pedoe, K. Kuulasmaa, M. Mähönen, H. Tolonen, E. Ruokokoski, and P. Amouyel Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease Lancet 353 1999 1547 1557
14. R.J. Goldberg, K. Glatfelter, E. Burbank-Schmidt, D. Lessard, and J.M. Gore Trends in community mortality due to coronary heart disease Am Heart J 151 2006 501 507
15. P.W. Armstrong, C.B. Granger, P.X. Adams, C. Hamm, D. Holmes Jr, and W.W. O'Neill Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial JAMA 297 2007 43 51
16. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet. 2006;367:569-78.
17. K.A. Fox, O.H. Dabbous, R.J. Goldberg, K.S. Pieper, K.A. Eagle, and F. Van de Werf Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) BMJ 333 2006 1091 1094
18. M.R. Le May, D.Y. So, R. Dionne, C.A. Glover, M.P. Froeschl, and G.A. Wells A citywide protocol for primary PCI in STsegment elevation myocardial infarction N Engl J Med 358 2008 231 240
19. J.P. Bassand, N. Danchin, G. Filippatos, A. Gitt, C. Hamm, and S. Silber Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology Eur Heart J 26 2005 2733 2741
20. K.L. Lee, L.H. Woodlief, E.J. Topol, W.D. Weaver, A. Betriu, and J. Col Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators Circulation 91 1995 1659 1668
21. D.A. Morrow, E.M. Antman, A. Charlesworth, R. Cairns, S.A. Murphy, and J.A. De Lemos TIMI risk score for STelevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy Circulation 102 2000 2031 2037
22. European Resuscitation Council European Resuscitation Council guidelines for resuscitation 2005 Resuscitation 67 Suppl 1 2005 S3 S189
23. A. Schomig, J. Mehilli, D. Antoniucci, G. Ndrepepa, C. Markwardt, and F. Di Pede Beyond 12 h Reperfusion AlternatiVe Evaluation (BRAVE-2) Trial Investigators. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial JAMA 293 2005 2865 2872
24. J.S. Hochman, G.A. Lamas, C.E. Buller, V. Dzavik, H.R. Reynolds, and S.J. Abramsky Coronary intervention for persistent occlusion after myocardial infarction N Engl J Med 355 2006 2395 2407
25. Menon V, Pearte CA, Buller CE, Steg PG, Forman SA, White HD, et al. Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery Trial. Eur Heart J. 2008 [en prensa].
26. S. Silber, P. Albertsson, F.F. Avilés, P.G. Camici, A. Colombo, and C. Hamm Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur Heart J 26 2005 804-647
27. J.G. Canto, N.R. Every, D.J. Magid, W.J. Rogers, J.A. Malmgren, and P.D. Frederick The volume of primary angioplasty procedures and survival after acute myocardial infarction. National Registry of Myocardial Infarction 2 Investigators N Engl J Med 342 2000 1573 1580
28. C. Spaulding, M.C. Morice, B. Lancelin, S. El Haddad, E. Lepage, and S. Bataille Is the volume-outcome relation still an issue in the era of PCI with systematic stenting? Results of the greater Paris area PCI registry Eur Heart J 27 2006 1054 1060
29. E.C. Keeley, J.A. Boura, and C.L. Grines Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials Lancet 361 2003 13 20
30. C.L. Grines, D.A. Cox, G.W. Stone, E. Garcia, L.A. Mattos, and A. Giambartolomei Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group N Engl J Med 341 1999 1949 1956
31. G.W. Stone, C.L. Grines, D.A. Cox, E. Garcia, J.E. Tcheng, and J.J. Griffin Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction N Engl J Med 346 2002 957 966
32. C. Spaulding, P. Henry, E. Teiger, K. Beatt, E. Bramucci, and D. Carrie Sirolimus-eluting versus uncoated stents in acute myocardial infarction N Engl J Med 355 2006 1093 1104
33. G.J. Laarman, M.J. Suttorp, M.T. Dirksen, L. Van Heerebeek, F. Kiemeneij, and T. Slagboom Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention N Engl J Med 355 2006 1105 1113
34. A. Kastrati, A. Dibra, C. Spaulding, G.J. Laarman, M. Menichelli, and M. Valgimigli Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction Eur Heart J 28 2007 2706 2713
35. G. De Luca, H. Suryapranata, F. Zijlstra, A.W. Van't Hof, J.C. Hoorntje, and A.T. Gosselink Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty J Am Coll Cardiol 42 2003 991 997
36. B. Nallamothu, K.A. Fox, B.M. Kennelly, F. Van de Werf, J.M. Gore, and P.G. Steg Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events Heart 93 2007 1552 1555
37. B.K. Nallamothu, and E.R. Bates Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol 92 2003 824 826
38. A. Betriu, and M. Masotti Comparison of mortality rates in acute myocardial infarction treated by percutaneous coronary intervention versus fibrinolysis Am J Cardiol 95 2005 100 101
39. B.K. Nallamothu, E.M. Antman, and E.R. Bates Primary percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: does the choice of fibrinolytic agent impact on the importance of time-to-treatment? Am J Cardiol 94 2004 772 774
40. E. Boersma Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients Eur Heart J 27 2006 779 788
41. D.S. Pinto, A.J. Kirtane, B.K. Nallamothu, S.A. Murphy, D.J. Cohen, and R.J. Laham Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy Circulation 114 2006 2019 2025
42. A. Kastrati, J. Mehilli, S. Nekolla, H. Bollwein, S. Martinoff, and J. Pache A randomized trial comparing myocardial salvage achieved by coronary stenting versus balloon angioplasty in patients with acute myocardial infarction considered ineligible for reperfusion therapy J Am Coll Cardiol 43 2004 734 741
43. J.S. Hochman, L.A. Sleeper, J.G. Webb, T.A. Sanborn, H.D. White, and J.D. Talley Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock N Engl J Med 341 1999 625 634
44. S.G. Ellis, M. Tendera, M.A. De Belder, A.J. Van Boven, P. Widimsky, L. Janssens FINESSE Investigators Facilitated PCI in patients with ST-elevation myocardial infarction N Engl J Med 358 2008 2205 2217
45. A.W. Van't Hof, J. Ten Berg, T. Heestermans, T. Dill, R.C. Funck, W. Van Werkum Ongoing Tirofiban In Myocardial infarction Evaluation (On-TIME) 2 study group Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial Lancet 372 2008 537 546
46. A.H. Gershlick, A. Stephens-Lloyd, S. Hughes, K.R. Abrams, S.E. Stevens, and N.G. Uren Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction N Engl J Med 353 2005 2758 2768
47. H.C. Wijeysundera, R. Vijayaraghavan, B.K. Nallamothu, J.M. Foody, H.M. Krumholz, and C.O. Phillips Rescue angioplasty or repeat fibrinolysis after failed fibrinolytic therapy for STsegment myocardial infarction: a meta-analysis of randomized trials J Am Coll Cardiol 49 2007 422 430
48. G.H. Gislason, S. Jacobsen, J.N. Rasmussen, S. Rasmussen, P. Buch, and J. Friberg Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nosteroidal antiinflammatory drugs after acute myocardial infarction Circulation 113 2006 2906 2913
49. E.M. Antman, J.S. Bennett, A. Daugherty, C. Furberg, H. Roberts, and K.A. Taubert Use of nonsteroidal antiinflammatory drugs: an update for clinicians. A scientific statement from the American Heart Association Circulation 115 2007 326 332
50. K.A. Fox, S.R. Mehta, R. Peters, F. Zhao, N. Lakkis, and B.J. Gersh Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial Circulation 110 2004 1202 1208
51. S.C. Beinart, P. Kolm, E. Veledar, Z. Zhang, E.M. Mahoney, and O. Bouin Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial J Am Coll Cardiol 46 2005 761 769
52. M.S. Sabatine, C.P. Cannon, C.M. Gibson, J.L. López-Sendon, G. Montalescot, and P. Theroux Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 352 2005 1179 1189
53. N. Von Beckerath, D. Taubert, G. Pogatsa-Murray, E. Schomig, A. Kastrati, and A. Schomig Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial Circulation 112 2005 2946 2950
54. G. Montalescot, G. Sideris, C. Meuleman, C. Bal-dit-Sollier, N. Lellouche, and P.G. Steg A randomized comparison of high clopidogrel loading doses in patients with non-STsegment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial J Am Coll Cardiol 48 2006 931 938
55. G. De Luca, H. Suryapranata, G.W. Stone, D. Antoniucci, J.E. Tcheng, and F.J. Neumann Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials JAMA 293 2005 1759 1765
56. G.W. Stone, B. Witzenbichler, G. Guagliumi, J.Z. Peruga, B.R. Brodie, and D. Dudek HORIZONS-AMI Trial Investigators. Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230
57. S. Yusuf, S.R. Mehta, S. Chrolavicius, R. Afzal, J. Pogue, and C.B. Granger Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial JAMA 295 2006 1519 1530
58. F. Burzotta, L. Testa, F. Giannico, G.G. Biondi-Zoccai, C. Trani, and E. Romagnoli Adjunctive devices in primary or rescue PCI: a meta-analysis of randomized trials Int J Cardiol 123 2008 313 321
59. T. Svilaas, P.J. Vlaar, I.C. Van der Horst, G.F. Diercks, B.J. De Smet, and A.F. Van den Heuvel Thrombus aspiration during primary percutaneous coronary intervention N Engl J Med 358 2008 557 567
60. P.J. Vlaar, T. Svilaas, I.C. Van der Horst, G.F. Diercks, M.L. Fokkema, and B.J. De Smet Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute myocardial infarction Study (TAPAS): a 1-year follow-up study Lancet 371 2008 1915 1920
61. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients Lancet 343 1994 311 322
62. H. White Thrombolytic therapy in the elderly Lancet 356 2000 2028 2030
63. L.J. Morrison, P.R. Verbeek, A.C. McDonald, B.V. Sawadsky, and D.J. Cook Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis JAMA 283 2000 2686 2692
64. H. Boersma, A.C. Maas, J.W. Deckers, and M.L. Simoons Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour Lancet 348 1996 771 775
65. P.G. Steg, E. Bonnefoy, S. Chabaud, F. Lapostolle, P.Y. Dubien, and P. Cristofini Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial Circulation 108 2003 2851 2856
66. N. Danchin, P. Coste, J. Ferrires, P.-G. Steg, Y. Cottin, D. Blanchard The FAST-MI Investigators Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the French Registry on Acute STElevation Myocardial Infarction (FAST-MI) Circulation 118 2008 268 276
67. K. Kalla, G. Christ, R. Karnik, R. Malzer, G. Norman, and H. Prachar Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in STelevation myocardial infarction (Vienna STEMI registry) Circulation 113 2006 2398 2405
68. J.M. Gore, C.B. Granger, M.L. Simoons, M.A. Sloan, W.D. Weaver, and H.D. White Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries Circulation 92 1995 2811 2818
69. F. Van de Werf, J. Adgey, D. Ardissino, P.W. Armstrong, P. Aylward, G. Barbash Investigators Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial Lancet 354 1999 716 722
70. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators A comparsion of reteplase with alteplase for acute myocardial infarction N Engl J Med 337 1997 1118 1123
71. S.D. Berkowitz, C.B. Granger, K.S. Pieper, K.L. Lee, J.M. Gore, and M. Simoons Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators Circulation 95 1997 2508 2516
72. The GUSTO Investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 329 1993 673 682
73. Böttiger BW, Arntz HR, Chamberlain DA, Bluhmki E, Belmans A, Danays T, et al for the Thrombolysis in Cardiac Arrest (TROICA)-Investigators and the European Resuscitation Council (ERC) Study Group. Thrombolysis during resuscitation for out-of-hospital cardiac arrest. N Engl J Med. 2008 [en prensa].
74. G.I. Barbash, Y. Birnbaum, K. Bogaerts, M.P. Hudson, E. Lesaffre, and Y. Fu Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO I) and assessment of the safety of a new thrombolytic (ASSENT 2) studies Circulation 103 2001 954 960
75. C. Di Mario, D. Dudek, F. Piscione, W. Mielecki, S. Savonitto, and E. Murena Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial Lancet 371 2008 559 568
76. F. Fernández-Avilés, J.J. Alonso, G. Pena, J. Blanco, J. Alonso-Briales, and J. López-Mesa Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial Eur Heart J 28 2007 949 960
77. M.R. Le May, G.A. Wells, M. Labinaz, R.F. Davies, M. Turek, and D. Leddy Combined angioplasty and pharmacological intervention versus thrombolysis alone in acute myocardial infarction (CAPITAL AMI study) J Am Coll Cardiol 46 2005 417 424
78. F. Fernández-Avilés, J.J. Alonso, A. Castro-Beiras, N. Vázquez, J. Blanco, and J. Alonso-Briales Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial Lancet 364 2004 1045 1053
79. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 Lancet ii 1988 349 360
80. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1607 1621
81. E.J. Topol For The GUSTO V investigators Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial Lancet 357 2001 1905 1914
82. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction Lancet 358 2001 605 613
83. D. De Bono, M.L. Simoons, J. Tijssen, A.E. Arnold, A. Betriu, and C. Burgersdijk Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial Br Heart J 67 1992 122 128
84. The GUSTO Angiographic Investigators The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction N Engl J Med 329 1993 1615 1622
85. P.L. Thompson, P.E. Aylward, J. Federman, R.W. Giles, P.J. Harris, and R.L. Hodge A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 h after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group Circulation 83 1991 1534 1542
86. C.B. Granger, J. Hirsch, R.M. Califf, J. Col, H.D. White, and A. Betriu Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial Circulation 93 1996 870 878
87. L. Wallentin, P. Goldstein, P.W. Armstrong, C.B. Granger, A.A. Adgey, and H.R. Arntz Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction Circulation 108 2003 135 142
88. R.R. Giraldez, J.C. Nicolau, R. Corbalán, E.P. Gurfinkel, U. Juárez, and J. López-Sendon Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of the choice of lytic: an ExTRACT-TIMI 25 analysis Eur Heart J 28 2007 1566 1573
89. H.D. White, E. Braunwald, S.A. Murphy, A.J. Jacob, N. Gotcheva, and L. Polonetsky Enoxaparin vs. unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25 Eur Heart J 28 2007 1066 1071
90. R.J. Peters, C. Joyner, J.P. Bassand, R. Afzal, S. Chrolavicius, S.R. Mehta For the OASIS-6 Investigators The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial Eur Heart J 29 2008 324 331
91. The Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving flbrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial Lancet 358 2001 1855 1863
92. M. Cohen, G.F. Gensini, F. Maritz, E.P. Gurfinkel, K. Huber, and A. Timerman The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute STsegment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial J Am Coll Cardiol 42 2003 1348 1356
93. J. Oldgren, L. Wallentin, R. Afzal, J.P. Bassand, A. Budaj, and S. Chrolavicius Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment Eur Heart J 29 2007 315 323
94. S.R. Mehta, S. Yusuf, R. Diaz, J. Zhu, P. Pais, and D. Xavier Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial JAMA 293 2005 437 446
95. J. Oldgren, L. Wallentin, R. Afzal, J.P. Bassand, A. Budaj, S. Chrolavicius For the OASIS-6 Investigators Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment Eur Heart J 29 2008 315 323
96. H. Ito, T. Tomooka, N. Sakai, H. Yu, Y. Higashino, and K. Fujii Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction Circulation 85 1992 1699 1705
97. H. Ito, A. Maruyama, K. Iwakura, S. Takiuchi, T. Masuyama, and M. Hori Clinical implications of the 'no reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction Circulation 93 1996 223 228
98. R.V. Kelly, M.G. Cohen, M.S. Runge, and G.A. Stouffer The noreflow phenomenon in coronary arteries J Thromb Haemost 2 2004 1903 1907
99. A. Maes, F. Van de Werf, J. Nuyts, G. Bormans, W. Desmet, and L. Mortelmans Impaired myocardial tissue perfusion early after successful thrombolysis. Impact on myocardial flow, metabolism, and function at late follow-up Circulation 92 1995 2072 2078
100. S. Kaul, and H. Ito Microvasculature in acute myocardial ischemia: part II: evolving concepts in pathophysiology, diagnosis, and treatment Circulation 109 2004 310 315
101. D.M. Yellon, and D.J. Hausenloy Myocardial reperfusion injury N Engl J Med 357 2007 1121 1135
102. P. Sorajja, B.J. Gersh, C. Costantini, M.G. McLaughlin, P. Zimetbaum, and D.A. Cox Combined prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction Eur Heart J 26 2005 667 674
103. L. Galiuto, S. Barchetta, S. Paladini, G. Lanza, A.G. Rebuzzi, and M. Marzilli Functional and structural correlates of persistent ST elevation after acute myocardial infarction successfully treated by percutaneous coronary intervention Heart 93 2007 1376 1380
104. H. Ito No-reflow phenomenon and prognosis in patients with acute myocardial infarction Nat Clin Pract Cardiovas Med 3 2006 499 506
105. K. Iwakura, H. Ito, S. Takiuchi, Y. Taniyama, Y. Nakatsuchi, and S. Negoro Alternation in the coronary blood flow velocity pattern in patients with no reflow and reperfused acute myocardial infarction Circulation 94 1996 1269 1275
106. F.H. Sheehan, E. Braunwald, P. Canner, H.T. Dodge, J. Gore, and P. Van Natta The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissuetype plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial Circulation 75 1987 817 829
107. A.W. Van't Hof, A. Liem, H. Suryapranata, J.C. Hoorntje, M.J. De Boer, and F. Zijlstra Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group Circulation 97 1998 2302 2306
108. E. Eeckhout, and M.J. Kern The coronary no-reflow phenomenon: a review of mechanisms and therapies Eur Heart J 22 2001 729 739
109. A.M. Ross, R.J. Gibbons, G.W. Stone, R.A. Kloner, and R.W. Alexander A randomized, double-blinded, placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II) J Am Coll Cardiol 45 2005 1775 1780
110. J.A. De Lemos, E.M. Antman, C.M. Gibson, C.H. McCabe, R.P. Giugliano, and S.A. Murphy Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial Circulation 101 2000 239 243
111. A.S. Petronio, D. Rovai, G. Musumeci, R. Baglini, C. Nardi, and U. Limbruno Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty Eur Heart J 24 2003 67 76
112. M. Thielmann, P. Massoudy, M. Neuhauser, K. Tsagakis, G. Marggraf, and M. Kamler Prognostic value of preoperative cardiac troponin I in patients undergoing emergency coronary artery bypass surgery with non-ST-elevation or ST-elevation acute coronary syndromes Circulation 114 Suppl I 2006 I448 I453
113. D.C. Lee, M.C. Oz, A.D. Weinberg, and W. Ting Appropriate timing of surgical intervention after transmural acute myocardial infarction J Thorac Cardiovasc Surg 125 2003 115 119
114. P Nicod Jr, E. Gilpin, H. Dittrich, F. Chappuis, S. Ahnve, and R. Engler Influence on prognosis and morbidity of left ventricular ejection fraction with and without signs of left ventricular failure after acute myocardial infarction Am J Cardiol 61 1988 1165 1171
115. K. Dickstein, A. Cohen-Solal, G. Filippatos, J.J.V. McMurray, P. Ponikowski, and P.A. Poole-Wilson ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 Eur Heart J 29 2008 2388 2442
116. J.S. Hochman, L.A. Sleeper, H.D. White, V. Dzavik, S.C. Wong, and V. Menon One-year survival following early revascularization for cardiogenic shock JAMA 285 2001 190 192
117. B.G. Leshnower, T.G. Gleason, M.L. O'Hara, A. Pochettino, Y.J. Woo, and R.J. Morris Safety and efficacy of left ventricular assist device support in postmyocardial infarction cardiogenic shock Ann Thorac Surg 81 2006 1365 1370
118. W. Tayara, R.C. Starling, M.H. Yamani, O. Wazni, F. Jubran, and N. Smedira Improved survival after acute myocardial infarction complicated by cardiogenic shock with circulatory support and transplantation: comparing aggressive intervention with conservative treatment J Heart Lung Transplant 25 2006 504 509
119. H. Thiele, R.W. Smalling, and G.C. Schuler Percutaneous left ventricular assist devices in acute myocardial infarction complicated by cardiogenic shock Eur Heart J 28 2007 2057 2063
120. R.G. Cummings, R. Califf, R.N. Jones, K.A. Reimer, Y.-H. Kong, and J.E. Lowe Correlates of survival in patients with postinfarction ventricular septal defect Ann Thorac Surg 47 1989 824 830
121. R. Lemery, H.C. Smith, E.R. Giuliani, and B.J. Gersh Prognosis in rupture of the ventricular septum after acute myocardial infarction and role of early surgical intervention Am J Cardiol 70 1992 147 151
122. O. Topaz, and A.L. Taylor Interventricular septal rupture complicating acute myocardial infarction: from pathophysiologic features to the role of invasive and noninvasive diagnostic modalities in current management Am J Med 93 1992 683 688
123. P. Chevalier, H. Burri, F. Fahrat, M. Cucherat, O. Jegaden, and J.F. Obadia Perioperative outcome and long-term survival of surgery for acute post-infarction mitral regurgitation Eur J Cardiothorac Surg 26 2004 330 335
124. Q. Chen, M.J. Darlymple-Hay, C. Alexiou, S.K. Ohri, M.P. Haw, and S.A. Livesey Mitral valve surgery for acute papillary muscle rupture following myocardial infarction Heart Valve Dis 11 2002 27 31
125. K.H. Newby, T. Thompson, A. Stebbins, E.J. Topol, R.M. Califf, and A. Natale Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators Circulation 98 1998 2567 2573
126. D.M. Henkel, B.J. Witt, B.J. Gersh, S.J. Jacobsen, S.A. Weston, and R.A. Meverden Ventricular arrhythmias after acute myocardial infarction: a 20-year community study Am Heart J 151 2006 806 812
127. H. Huikuri, A. Castellanos, and R. Myerburg Sudden death due to cardiac arrhythmias N Engl J Med 345 2001 1473 1482
128. R.A. Gardner, W.B. Kruyer, J.S. Pickard, and P.V. Celio Nonsustained ventricular tachycardia in 193 U.S. military aviators: longterm follow-up Aviat Space Environ Med 71 2000 783 790
129. A. Hjalmarson Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period Am J Cardiol 80 1997 J35 J39
130. D.P. Zipes, A.J. Camm, M. Borggrefe, A.E. Buxton, B. Chaitman, and M. Fromer ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Eur Heart J 27 2006 2099 2140
131. S.S. Rathore, A.K. Berger, K.P. Weinfurt, K.A. Schulman, W.J. Oetgen, and B.J. Gersh Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes Circulation 101 2000 969 974
132. V. Fuster, L.E. Ryden, D.S. Cannom, H.J. Crijns, A.B. Curtis, and K.A. Ellenbogen ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society Circulation 114 2006 e257 e354
133. J.A. Goldstein, D.T. Lee, M.C. Pica, S.R. Dixon, and W.W. O'Neill Patterns of coronary compromise leading to bradyarrhythmias and hypotension in inferior myocardial infarction Coronary Artery Dis 16 2005 265 274
134. T.J. Meine, S.M. Al-Khatib, J.H. Alexander, C.B. Granger, H.D. White, and R. Kilaru Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy Am Heart J 149 2005 670 674
135. K.H. Newby, E. Pisano, M.W. Krucoff, C. Green, and A. Natale Incidence and clinical relevance of the occurrence of bundlebranch block in patients treated with thrombolytic therapy Circulation 94 1996 2424 2428
136. G. Gregoratos Jr, J. Abrams, A.E. Epstein, R.A. Freedman, D.L. Hayes, and M.A. Hlatky ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines) Circulation 106 2002 2145 2161
137. P.E. Vardas, A. Auricchio, J.J. Blanc, J.C. Daubert, H. Drexler, and H. Ector Guidelines for cardiac pacing and cardiac resynchronization therapy: the task force for cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association Eur Heart J 28 2007 2256 2295
138. R. Roberts, W.J. Rogers, H.S. Mueller, C.T. Lambrew, D.J. Diver, H.C. Smith For the TIMI Investigators Immediate versus deferred betablockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study Circulation 83 1991 422 437
139. F. Van de Werf, L. Janssens, T. Brzostek, L. Mortelmans, F.J. Wackers, and G.M. Willems Short-term effects of early intravenous treatment with a beta-adrenergic blocking agent or a specific bradycardiac agent in patients with acute myocardial infarction receiving thrombolytic therapy J Am Coll Cardiol 22 1993 407 416
140. M. Pfisterer, J.L. Cox, C.B. Granger, S.J. Brener, C.D. Naylor, and R.M. Califf Atenolol use and clinical outcomes after thrombolysis for acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA (alteplase) for Occluded Coronary Arteries J Am Coll Cardiol 32 1998 634 640
141. N. Freemantle, J. Cleland, P. Young, J. Mason, and J. Harrison Beta blockade after myocardial infarction: systematic review and meta regression analysis BMJ 318 1999 1730 1737
142. COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial Lancet 366 2005 1622 1632
143. GISSI-3 Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico Lancet 343 1994 1115 1122
144. ISIS-4 A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group Lancet 345 1995 669 685
145. S. Yusuf, P. Held, and C. Furberg Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies Am J Cardiol 67 1991 1295 1297
146. Chinese Cardiac Study Collaborative Group Oral captopril versus placebo among 13,634 patients with suspected myocardial infarction: interim report from the Chinese Cardiac study (CCS-1) Lancet 345 1995 686 687
147. M.A. Pfeffer, and C.H. Hennekens When a question has an answer: rationale for our early termination of the HEART trial Am J Cardiol 75 1995 1173 1175
148. Antman E. The MAGIC trial. Presented at the XXIVth Scientific Sessions of the European Society of Cardiology in Berlin, September 2002.
149. B.R. Brodie, T.D. Stuckey, C. Hansen, B.H. Bradshaw, W.E. Downey, and M.W. Pulsipher Comparison of late survival in patients with cardiogenic shock due to right ventricular infarction versus left ventricular pump failure following primary percutaneous coronary intervention for ST-elevation acute myocardial infarction Am J Cardiol 99 2007 431 435
150. U. Zeymer, K.L. Neuhaus, K. Wegscheider, U. Tebbe, P. Molhoek, R. Schroder Effects of thrombolytic therapy in acute inferior myocardial infarction with or without right ventricular involvement. HIT-4 Trial Group Hirudin for Improvement of Thrombolysis J Am Coll Cardiol 32 1998 876 881
151. S.M. Donahoe, G.C. Stewart, C.H. McCabe, S. Mohanavelu, S.A. Murphy, and C.P. Cannon Diabetes and mortality following acute coronary syndromes JAMA 298 2007 765 775
152. K.H. Mak, D.J. Moliterno, C.B. Granger, D.P. Miller, H.D. White, and R.G. Wilcox Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries J Am Coll Cardiol 30 1997 171 179
153. D.K. McGuire, H. Emanuelsson, C.B. Granger, E. Magnus Ohman, D.J. Moliterno, and H.D. White Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators Eur Heart J 21 2000 1750 1758
154. S.M. Haffner, S. Lehto, T. Ronnemaa, K. Pyorala, and M. Laakso Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction N Engl J Med 339 1998 229 234
155. M. Laakso Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention J Intern Med 249 2001 225 235
156. M.T. Roe, E.D. Peterson, L.K. Newby, A.Y. Chen, C.V. Pollack Jr, and R.G. Brindis The influence of risk status on guideline adherence for patients with non-ST-segment elevation acute coronary syndromes Am Heart J 151 2006 1205 1213
157. A. Norhammar, K. Malmberg, L. Ryden, P. Tornvall, U. Stenestrand, and L. Wallentin Under utilisation of evidencebased treatment partially explains the unfavourable prognosis in diabetic patients with acute myocardial infarction Eur Heart J 24 2003 838 844
158. K.W. Mahaffey, C.B. Granger, C.A. Toth, H.D. White, A.L. Stebbins, and G.I. Barbash Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries J Am Coll Cardiol 30 1997 1606 1610
159. M. Anselmino, M. Bartnik, K. Malmberg, and L. Ryden Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the Heart Eur J Cardiovasc Prev Rehabil 14 2007 28 36
160. K. Malmberg, J. Herlitz, A. Hjalmarson, and L. Ryden Effects of metoprolol on mortality and late infarction in diabetics with suspected acute myocardial infarction. Retrospective data from two large studies Eur Heart J 10 1989 423 428
161. U. Stenestrand, and L. Wallentin Early statin treatment following acute myocardial infarction and 1-year survival JAMA 285 2001 430 436
162. J.J. Cao, M. Hudson, M. Jankowski, F. Whitehouse, and W.D. Weaver Relation of chronic and acute glycemic control on mortality in acute myocardial infarction with diabetes mellitus Am J Cardiol 96 2005 183 186
163. K. Malmberg, A. Norhammar, H. Wedel, and L. Ryden Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) study Circulation 99 1999 2626 2632
164. K. Malmberg, L. Ryden, S. Efendic, J. Herlitz, P. Nicol, and A. Waldenstrom Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year J Am Coll Cardiol 26 1995 57 65
165. K. Malmberg, L. Ryden, A. Hamsten, J. Herlitz, A. Waldenstrom, and H. Wedel Effects of insulin treatment on cause-specific oneyear mortality and morbidity in diabetic patients with acute myocardial infarction. DIGAMI Study Group. Diabetes Insulin-Glucose in Acute Myocardial Infarction Eur Heart J 17 1996 1337 1344
166. K. Malmberg Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group BMJ 314 1997 1512 1515
167. K. Malmberg, L. Ryden, H. Wedel, K. Birkeland, A. Bootsma, and K. Dickstein Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity Eur Heart J 26 2005 650 661
168. P. Deedwania, M. Kosiborod, E. Barrett, A. Ceriello, W. Isley, and T. Mazzone Hyperglycemia and acute coronary syndrome. A Scientific Statement From the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism Circulation 117 2008 1610 1619
169. A.M. Svensson, D.K. McGuire, P. Abrahamsson, and M. Dellborg Association between hyper- and hypoglycaemia and 2 year all-cause mortality risk in diabetic patients with acute coronary events Eur Heart J 26 2005 1245 1248
170. M.J. Sarnak, A.S. Levey, A.C. Schoolwerth, J. Coresh, B. Culleton, and L.L. Hamm Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Hypertension 42 2003 1050 1065
171. N.S. Anavekar, J.J. McMurray, E.J. Velazquez, S.D. Solomon, L. Kober, and J.L. Rouleau Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction N Engl J Med 351 2004 1285 1295
172. A.R. Assali, D. Brosh, I. Ben-Dor, A. Solodky, S. Fuchs, and I. Teplitsky The impact of renal insufficiency on patients' outcomes in emergent angioplasty for acute myocardial infarction Catheter Cardiovasc Interv 69 2007 395 400
173. S. Behar, Y. Kishon, H. Reicher-Reiss, M. Zion, E. Kaplinsky, and E. Abinader Prognosis of early versus late ventricular fibrillation complicating acute myocardial infarction Int J Cardiol 45 1994 191 198
174. J. Brugada, L. Aguinaga, L. Mont, A. Betriu, J. Mulet, and G. Sanz Coronary artery revascularization in patients with sustained ventricular arrhythmias in the chronic phase of a myocardial infarction: effects on the electrophysiologic substrate and outcome J Am Coll Cardiol 37 2001 529 533
175. A. Natale, J. Sra, K. Axtell, C. Maglio, A. Dhala, and Z. Blanck Ventricular fibrillation and polymorphic ventricular tachycardia with critical coronary artery stenosis: does bypass surgery suffice? J Cardiovasc Electrophysiol 5 1994 988 994
176. G.H. Bardy, K.L. Lee, D.B. Mark, J.E. Poole, D.L. Packer, and R. Boineau Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure N Engl J Med 352 2005 225 237
177. D.S. Lee, L.D. Green, P.P. Liu, P. Dorian, D.M. Newman, and F.C. Grant Effectiveness of implantable defibrillators for preventing arrhythmic events and death: a meta-analysis J Am Coll Cardiol 41 2003 1573 1582
178. J. Ezekowitz, P. Armstrong, and F. McAlister Implantable cardioverter defibrillators in primary and secondary prevention: a systematic review of randomized, controlled trials Ann Intern Med 138 2003 445 452
179. B.H. Sarter, J.K. Finkle, R.E. Gerszten, and A.E. Buxton What is the risk of sudden cardiac death in patients presenting with hemodynamically stable sustained ventricular tachycardia after myocardial infarction? J Am Coll Cardiol 28 1996 122 129
180. K.A. Fox, F.A. Anderson Jr, O.H. Dabbous, P.G. Steg, J. Lopez-Sendon, F. Van de Werf GRACE Investigators Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE) Heart 93 2007 177 182
181. B. Sitt, J. Loscalzo, J. Ycas, and J.S. Raichlen Lipid levels after acute coronary syndromes J Am Coll Cardiol 51 2008 1440 1445
182. A.F. Schinkel, J.J. Bax, D. Poldermans, A. Elhendy, R. Ferrari, and S.H. Rahimtoola Hibernating myocardium: diagnosis and patient outcomes Curr Probl Cardiol 32 2007 375 410
183. T. Chow, D.J. Kereiakes, C. Bartone, T. Booth, E.J. Schloss, and T. Waller Prognostic utility of microvolt T-wave alternans in risk stratification of patients with ischemic cardiomyopathy J Am Coll Cardiol 47 2006 1820 1827
184. I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, and G. Burell European guidelines on cardiovascular disease prevention in clinical practice: executive summary Eur Heart J 28 2007 2375 2414
185. Jolly K, Lip GY, Taylor RS, Raftery JP, Mant JW, Lane D, et al. The Birmingham Rehabilitation Uptake Maximisation study (BRUM): a randomised controlled trial comparing home-based with centre-based cardiac rehabilitation. Heart. 2008 Mar 10 [Epub ahead of print].
186. P. Giannuzzi, A. Mezzani, H. Saner, H. Björnstad, P. Fioretti, M. Mendes Working Group on Cardiac Rehabilitation and Exercise Physiology European Society of Cardiology. Physical activity for primary and secondary prevention. Position paper of the Working Group on Cardiac Rehabilitation and Exercise Physiology of the European Society of Cardiology Eur Heart J 24 2003 1273 1278
187. A. Rozanski, J.A. Blumenthal, K.W. Davidson, P.G. Saab, and L. Kubzansky The epidemiology, pathophysiology, and management of psychosocial risk factors in cardiac practice: the emerging field of behavioral cardiology J Am Coll Cardiol 45 2005 637 651
188. K. Rees, P. Bennett, R. West, S.G. Davey, and S. Ebrahim Psychological interventions for coronary heart disease Cochrane Database Syst Rev 2 2004 CD002902
189. A. Nicholson, H. Kuper, and H. Hemingway Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies Eur Heart J 27 2006 2763 2774
190. G.T. O'Connor, J.E. Buring, S. Yusuf, S.Z. Goldhaber, E.M. Olmstead, and R.S. Paffenbarger Jr An overview of randomized trials of rehabilitation with exercise after myocardial infarction Circulation 80 1989 234 244
191. R.S. Taylor, A. Brown, S. Ebrahim, J. Jolliffe, H. Noorani, and K. Rees Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials Am J Med 116 2004 682 692
192. P. Buch, S. Rasmussen, G.H. Gislason, J.N. Rasmussen, L. Kober, and N. Gadsboll Temporal decline in the prognostic impact of a recurrent acute myocardial infarction 1985 to 2002 Heart 93 2007 210 215
193. A. Rosengren, L. Wallentin, M. Simoons, A.K. Gitt, S. Behar, and A. Battler Cardiovascular risk factors and clinical presentation in acute coronary syndromes Heart 91 2005 1141 1147
194. A. Aberg, R. Bergstrand, S. Johansson, G. Ulvenstam, A. Vedin, and H. Wedel Cessation of smoking after myocardial infarction. Effects on mortality after 10 years Br Heart J 49 1983 416 422
195. T.J. Meine, M.R. Patel, J.B. Washam, P.A. Pappas, and J.G. Jollis Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes Am J Cardiol 95 2005 976 978
196. C.B. Taylor, N. Houston-Miller, J.D. Killen, and R.F. DeBusk Smoking cessation after acute myocardial infarction: effects of a nurse-managed intervention Ann Intern Med 113 1990 118 123
197. A. Mead, G. Atkinson, D. Albin, D. Alphey, S. Baic, and O. Boyd Dietetic guidelines on food and nutrition in the secondary prevention of cardiovascular disease - evidence from systematic reviews of randomized controlled trials (second update, January 2006) J Hum Nutr Diet 19 2006 401 419
198. GISSI Prevenzione Investigators Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results from the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravivvenza nell'Infarto miocardico Lancet 354 1999 447 455
199. L. Hooper, R.L. Thompson, R.A. Harrison, C.D. Summerbell, A.R. Ness, and H.J. Moore Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review BMJ 332 2006 752 760
200. Rosengren A, Wallentin L, A KG, Behar S, Battler A, Hasdai D. Sex, age, and clinical presentation of acute coronary syndromes. Eur Heart J. 2004;25:663-70.
201. R.S. Taylor, A. Brown, S. Ebrahim, J. Jolliffe, H. Noorani, and K. Rees Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials Am J Med 116 2004 682 692
202. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
203. P. Smith, H. Arnesen, and I. Holme The effect of warfarin on mortality and reinfarction after myocardial infarction N Engl J Med 323 1990 147 152
204. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group Effect of longterm oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infraction Lancet 343 1994 499 503
205. F. Andreotti, L. Testa, G.G. Biondi-Zoccai, and F. Crea Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients Eur Heart J 27 2006 519 526
206. P.P. Karjalainen, P. Porela, A. Ylitalo, S. Vikman, K. Nyman, and M.A. Vaittinen Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting Eur Heart J 28 2007 726 732
207. A. Rubboli, M. Milandri, C. Castelvetri, and B. Cosmi Metaanalysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting Cardiology 104 2005 101 106
208. M.C. Nguyen, Y.L. Lim, A. Walton, J. Lefkovits, G. Agnelli, S.G. Goodman For the GRACE Investigators Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry ofAcute Coronary Events: is it safe and effective to use just one antiplatelet agent? Eur Heart J 28 2007 1717 1722
209. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, K.K. Fox Clopidogrel in Unstable Angina to Prevent Recurrent Events Trail Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
210. The Danish Study Group on Verapamil in Myocardial Infarction Effect of verapamil on mortality and major events after myocardial infarction (the Danish Verapamil Infarction Trial II-DAVIT II) Am J Cardiol 66 1990 779 785
211. The Multicenter Diltiazem Postinfarction Trial Research Group The effect of diltiazem on mortality and reinfarction after myocardial infarction N Engl J Med 319 1988 385 392
212. W.E. Boden, W.H. Van Gilst, R.G. Scheldewaert, I.R. Starkey, M.F. Carlier, and D.G. Julian Diltiazem in acute myocardial infarction treated with thrombolytic agents: a randomized placebo-controlled trial. Incomplete Infarction Trial of European Research Collaborators Evaluating Prognosis post-Thrombolysis (INTERCEPT) Lancet 355 2000 1751 1756
213. M.A. Pfeffer, E. Braunwald, L.A. Moye, L. Basta, E.J. Brown Jr, and T.E. Cuddy Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators N Engl J Med 327 1992 669 677
214. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure Lancet 342 1993 821 828
215. E. Ambrosioni, C. Borghi, and B. Magnani The effect of the angiotensinconverting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-term Evaluation (SMILE) Study Investigators N Engl J Med 332 1995 80 85
216. L. Kober, C. Torp-Pedersen, J.E. Carlsen, H. Bagger, P. Eliasen, and K. Lyngborg A clinical trial of the angiotensinconverting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group N Engl J Med 333 1995 1670 1676
217. ACE-Inhibitor Myocardial Infarction Collaborative Group Indications for ACEinhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomised trials Circulation 97 1998 2202 2212
218. G.R. Dagenais, J. Pogue, K. Fox, M.L. Simoons, and S. Yusuf Angiotensin-convertingenzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials Lancet 368 2006 581 588
219. M.H. Al-Mallah, I.M. Tleyjeh, A.A. Abdel-Latif, and W.D. Weaver Angiotensin-converting enzyme inhibitors in coronary artery disease and preserved left ventricular systolic function: a systematic review and meta-analysis of randomized controlled trials J Am Coll Cardiol 47 2006 1576 1583
220. N. Danchin, M. Cucherat, C. Thuillez, E. Durand, Z. Kadri, and P.G. Steg Angiotensinconverting enzyme inhibitors in patients with coronary artery disease and absence of heart failure or left ventricular systolic dysfunction: an overview of long-term randomized controlled trials Arch Intern Med 166 2006 787 796
221. K. Dickstein, and J. Kjekshus Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan Lancet 360 2002 752 760
222. M.A. Pfeffer, J.J. McMurray, E.J. Velazquez, J.L. Rouleau, L. Kober, and A.P. Maggioni Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906
223. B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, and B. Roniker Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 2003 1309 1321
224. G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, and G. Germano The task force for the management of arterial hypertension of the European Society of Hypertension, The task force for the management of arterial hypertension of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 28 2007 1462 1536
225. M. Bartnik, K. Malmberg, A. Norhammar, A. Tenerz, J. Ohrvik, and L. Rydén Newly detected abnormal glucose tolerance: an important predictor of long-term outcome after myocardial infarction Eur Heart J 25 2004 1990 1997
226. L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, and M.J. De Boer Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 2007 88 136
227. K. Josan, S.R. Majumdar, and F.A. McAlister The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials CMAJ 178 2008 576 584
228. H.B. Rubins, S.J. Robins, D. Collins, C.L. Fye, J.W. Anderson, and M.B. Elam Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of highdensity lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N Engl J Med 341 1999 410 418
229. The BIP Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study Circulation 102 2000 21 27
230. E.P. Gurfinkel, R. Leon de la Fuente, O. Mendiz, and B. Mautner Flu vaccination in acute coronary syndromes and planned percutaneous coronary interventions (FLUVACS) Study Eur Heart J 25 2004 25 31
231. A. Ciszewski, Z.T. Bilinska, L.B. Brydak, C. Kepka, M. Kruk, and M. Romanowska Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery disease: FLUCAD study Eur Heart J 29 2008 1350 1358
232. A.E. Buxton, K.L. Lee, J.D. Fisher, M.E. Josephson, E.N. Prystowsky, and G. Hafley A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators N Engl J Med 341 1999 1882 1890
233. K. Swedberg, J. Cleland, H. Dargie, H. Drexler, F. Follath, and M. Komajda Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology Eur Heart J 26 2005 1115 1140
234. J.G. Cleland, J. Ghosh, N. Freemantle, G.C. Kaye, M. Nasir, and A.L. Clark Clinical trials update and cumulative metaanalyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUSUS, RIO-Lipids and cardiac resynchronisation therapy in heart failure Eur J Heart Fail 6 2004 501 508
235. A.J. Moss, W. Zareba, W.J. Hall, H. Klein, D.J. Wilber, and D.S. Cannom Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction N Engl J Med 346 2002 877 883
236. V. Chevalier, C. Alauze, V. Soland, J. Cuny, and P. Goldstein Impact of a public-directed media campaign on emergency call to a mobile intensive care units center for acute chest pain Ann Cardiol Angeiol (Paris) 52 2003 150 158
237. C.J. Terkelsen, B.L. Norgaard, J.F. Lassen, and H.R. Andersen Prehospital evaluation in ST-elevation myocardial infarction patients treated with primary percutaneous coronary intervention J Electrocardiol 38 2005 187 192
238. C.B. Hutchings, N.C. Mann, M. Daya, J. Jui, R. Goldberg, and L. Cooper Patients with chest pain calling 9-1-1 or selftransporting to reach definitive care: which mode is quicker? Am Heart J 147 2004 35 41
239. B. Cabrita, F. Bouyer-Dalloz, I. L'Huillier, G. Dentan, M. Zeller, and Y. Laurent Beneficial effects of direct call to emergency medical services in acute myocardial infarction Eur J Emerg Med 11 2004 12 18
240. Y. Fukuoka, K. Dracup, M. Ohno, F. Kobayashi, and H. Hirayama Symptom severity as a predictor of reported differences of prehospital delay between medical records and structured interviews among patients with AMI Eur J Cardiovasc Nurs 4 2005 171 176
241. I. Johansson, A. Stromberg, and E. Swahn Ambulance use in patients with acute myocardial infarction J Cardiovasc Nurs 19 2004 5 12
242. W.D. Weaver, M. Cerqueira, A.P. Hallstrom, P.E. Litwin, J.S. Martin, and P.J. Kudenchuk Prehospital-initiated vs hospitalinitiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial JAMA 270 1993 1211 1216
243. GREAT Group Feasibility, safety and efficacy of domiciliary thrombolysis by general practitioners. Grampian region early anistreplase trial BMJ 305 1992 548 553
244. J.G. Canto, W.J. Rogers, L.J. Bowlby, W.J. French, D.J. Pearce, and W.D. Weaver The prehospital electrocardiogram in acute myocardial infarction: is its full potential being realized? National Registry of Myocardial Infarction 2 Investigators J Am Coll Cardiol 29 1997 498 505
245. M.R. Le May, R.F. Davies, R. Dionne, J. Maloney, J. Trickett, and D. So Comparison of early mortality of paramedic-diagnosed ST-segment elevation myocardial infarction with immediate transport to a designated primary percutaneous coronary intervention center to that of similar patients transported to the nearest hospital Am J Cardiol 98 2006 1329 1333
246. M.J. Bouten, M.L. Simoons, J.A. Hartman, A.J. Van Miltenburg, E. Van der Does, and J. Pool Prehospital thrombolysis with alteplase (rt-PA) in acute myocardial infarction Eur Heart J 13 1992 925 931
247. E.W. Grijseels, J.W. Deckers, A.W. Hoes, J.A. Hartman, E. Van der Does, and E. Van Loenen Pre-hospital triage of patients with suspected myocardial infarction. Evaluation of previously developed algorithms and new proposals Eur Heart J 16 1995 325 332
248. N. Hata, N. Kobayashi, T. Imaizumi, S. Yokoyama, T. Shinada, and J. Tanabe Use of an air ambulance system improves time to treatment of patients with acute myocardial infarction Intern Med 45 2006 45 50
249. M.C. Colquhoun, and D.G. Julian Treatable arrhythmias in cardiac arrests seen outside hospital Lancet 339 1992 1167
250. D.K. Moser, L.P. Kimble, M.J. Alberts, A. Alonzo, J.B. Croft, and K. Dracup Reducing delay in seeking treatment by patients with acute coronary syndrome and stroke: a scientific statement from the American Heart Association Council on cardiovascular nursing and stroke council Circulation 114 2006 168 182
251. W.S. Leslie, A. Urie, J. Hooper, and C.E. Morrison Delay in calling for help during myocardial infarction: reasons for the delay and subsequent pattern of accessing care Heart 84 2000 137 141
252. I.C. Rokos, D.M. Larson, T.D. Henry, W.J. Koenig, M. Eckstein, and W.J. French Rationale for establishing regional ST-elevation myocardial infarction receiving center (SRC) networks Am Heart J 152 2006 661 667
253. S. Harvey, D.A. Harrison, M. Singer, J. Ashcroft, C.M. Jones, and D. Elbourne PAC-Man study collaboration. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial Lancet 366 2005 472 477
254. The ESCAPE Investigators and ESCAPE Study Coordinators Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness. The ESCAPE Trial JAMA 294 2005 1625 1633
255. M.R. Shah, V. Hasselblad, L.W. Stevenson, C. Binanay, C.M. O'Conor, and G. Sopko Impact of the pulmonary artery catheter in critically ill patients. Meta-analysis of randomized clinical trials JAMA 294 2005 1664 1670
256. K.A. Fox, D.V. Cokkinos, J. Deckers, U. Keil, A. Maggioni, and G. Steg The ENACT study: a pan-European survey of acute coronary syndromes. European Network for Acute Coronary Treatment Eur Heart J 21 2000 1440 1449
257. The GRACE Investigators Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project: a multinational registry of patients hospitalized with acute coronary syndromes Am Heart J 141 2001 190 199
258. K.A. Eagle, B.K. Nallamothu, R.H. Mehta, C.B. Granger, P.G. Steg, F. Van de Werf For the Global Registry of Acute Coronary Events (GRACE) Investigators Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we are getting better but we have got a long way to go Eur Heart J 29 2008 609 617